Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy
Bin Tu, Meng Zhang, Tuanbing Liu, Yongzhuo Huang
Abstract
Histone deacetylase inhibitors (HDACi) have been approved and achieved success in hematologic malignancies. But its application in solid tumors still confronts big challenges and is hampered by low treatment efficacy. Nanotechnology has been widely applied in cancer therapy, and nanomedicine could improve drug stability, prolong the circulation half-life, and increase intratumoral drug accumulation. Therefore, nanomedicine is a promising strategy to enhance HDACi therapy efficacy. The review provides a summary of the advances of HDACi nanomedicines with a focus on the design principles of the targeting delivery systems for HDACi.
Topics & Concepts
NanomedicineHistone deacetylaseCancer therapyHistone deacetylase inhibitorDrug deliveryMedicineCancerVorinostatDrugCancer researchPharmacologyNanotechnologyHistoneChemistryInternal medicineMaterials scienceBiochemistryGeneNanoparticleHistone Deacetylase Inhibitors ResearchGraphene and Nanomaterials ApplicationsPeptidase Inhibition and Analysis